Nalidixic acid disk for laboratory detection of ciprofloxacin resistance in Neisseria meningitidis. 2009

Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
National Centre for Microbiology, National Institute of Health Carlos III, Majadahonda (Madrid), Spain.

Recently the CLSI recommended a disk diffusion method and breakpoints for meningococci which include breakpoints derived for nalidixic acid which serve as surrogate markers for gyrase A mutations associated with diminished fluoroquinolone susceptibility. This study presents the application of this methodology to a panel of 57 meningococcal strains isolated in Spain that include all levels of susceptibility to ciprofloxacin. In conclusion, the most useful method to predict isolates with gyrA mutations that decrease the activity of fluoroquinolones is the use of 30-microg nalidixic acid disks.

UI MeSH Term Description Entries
D008589 Meningococcal Infections Infections with bacteria of the species NEISSERIA MENINGITIDIS. Meningococcal Septicemia,Infections, Meningococcal,Meningococcal Disease,Infection, Meningococcal,Meningococcal Diseases,Meningococcal Infection,Septicemia, Meningococcal
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009268 Nalidixic Acid A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE. Nalidixin,Nalidixate Sodium,Nalidixate Sodium Anhydrous,Nevigramon,Sodium Nalidixic Acid, Anhydrous,Sodium Nalidixic Acid, Monohydrate,Acid, Nalidixic,Anhydrous, Nalidixate Sodium,Sodium Anhydrous, Nalidixate,Sodium, Nalidixate
D009345 Neisseria meningitidis A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype. Diplokokkus intracellularis meningitidis,Meningococcus,Micrococcus intracellularis,Micrococcus meningitidis,Micrococcus meningitidis cerebrospinalis,Neisseria weichselbaumii
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013030 Spain Country located between France on the northeast and Portugal on the west and bordered by the Atlantic Ocean and the Mediterranean Sea. The capital is Madrid. Balearic Islands,Canary Islands
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance

Related Publications

Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
August 2008, Emerging infectious diseases,
Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
March 2018, Journal of medical microbiology,
Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
August 2005, The Journal of antimicrobial chemotherapy,
Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
November 2009, Emerging infectious diseases,
Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
February 1991, Journal of clinical pathology,
Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
May 2003, The Journal of antimicrobial chemotherapy,
Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
October 2007, Emerging infectious diseases,
Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
May 2023, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
October 1987, Antimicrobial agents and chemotherapy,
Rocío Enríquez, and Raquel Abad, and Celia Salcedo, and Julio A Vázquez
March 2004, Medecine et maladies infectieuses,
Copied contents to your clipboard!